New research indicates that patients who stop using blockbuster weight-loss injections like semaglutide or tirzepatide can put back on shed pounds far faster than those who stop traditional diet and exercise plans.
Findings released in a major health publication points out that while obese individuals frequently drop substantial amounts of their body weight while using the jabs, the mass returns at an estimated rate of nearly a kilo each month upon discontinuation.
"Individuals using these drugs need to be aware of the risk of quick rebound weight gain when the medication is stopped," cautioned expert Dr. Susan Jebb.
That rate of regain implies a return to original mass within about a year and a half.
Analyzing Treatments
The analysis, which looked at dozens of trials involving thousands of patients, compared the effects of these new drugs with older methods.
The team note that people who shed pounds through diet and exercise generally experience a more gradual creep back—perhaps 0.1 kg a month—once they finish.
Understanding the Fast Rebound
Nutrition scientists propose the mechanism of the injections explains the accelerated regain.
GLP-1 drugs imitate a body's own chemical called GLP-1, which moderates feelings of fullness.
"Long-term administration of the hormone levels far above than normal could lead to the body to generate a reduced amount of its own natural GLP-1, and may also diminish responsiveness to its actions," explained Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this GLP-1 'fix' results in hunger is uncontrolled, making binge eating much more probable."
A Lifelong Issue?
Medical guidelines recommend the injections for people with obesity-related health risks, accompanied by prescribed diet and exercise modifications.
Many experts contend that, considering the likelihood of weight regain, the therapy should be considered life-long.
This view is supported by pharmaceutical companies, who say that the results "emphasize the long-term nature of excess weight," similar to managing conditions like diabetes.
Patient Experiences
Users who have discontinued the medication explain a intense resurgence of appetite.
"I experienced a trigger activating and you become extremely hungry," recalled an individual.
This challenge is exacerbated if individuals have not established lasting dietary or behavioural modifications during treatment.
Significant Use
Survey data suggest that millions of people in the UK have tried weight-loss jabs in the last 12 months, with desire being substantial.
- Adoption is greater among females compared to men.
- The 40s and 50s demographic shows the highest usage rates.
- Many obtain the drugs through private healthcare rather than the NHS.
Finally, experts emphasize that while GLP-1 drugs are effective tools for weight loss, they are not a magic solution and lasting health benefits likely depends on ongoing behavioural support.
